A preliminary estimate, and a request for better ones.
Summary
I believe the standard literature estimates for the number of DALYs attributable to a case of stunting are too low, largely because they don’t account for the long term effects. This means that childhood nutritional interventions that reduce the prevalence of stunting may be substantially more cost-effective than previously believed.
Epistemic status
Exploratory and back-o...
Note: This post was crossposted from Planned Obsolescence by the Forum team, with the author's permission. The author may not see or respond to comments on this post.
Subtitle: It’s a major warning shot, and might be the last one we get
All opinions are my personal view, and don’t represent my employer or fellow investigators.
This week, METR and Redwood Research published...
TL;DR: Kairos has raised $50 million from Coefficient Giving for two years of funding, one of the largest commitments they’ve made towards AI safety fieldbuilding to date. We’re using this to make an ambitious push for growing Kairos, broadening our portfolio of talent infrastructure projects and incubating new organizations. We’ve doubled in size in the last six mon...
New anti-malaria treatment clears phase 3 trials.
I just found that there is a new anti-malarial alternative to artemisinin, the most common antimalarial chemical, which has successfully completed Phase 3 trials. Its nickname is GanLum and apparently has quite powerful effects:
This is an important advance because resistance to artemisinin is one of the growing concerns in the fight against malaria.
You may read more in https://www.npr.org/sections/goats-and-soda/2025/11/12/g-s1-97487/malaria-drug-new and https://www.mmv.org/newsroom/news-resources-search/phase-3-trial-next-generation-malaria-treatment-ganaplacide-lumefantrine .
Very interesting! And very hopeful! Thanks for sharing!